Chimeric antigen receptor T-cell (CART) therapy in non-Hodgkin's lymphoma: the survival gain improves as more mature follow-up data become available.
作者信息
Messori Andrea, Bartoli Laura, Mengato Daniele, Chiumente Marco
机构信息
HTA Unit, Regione Toscana, Firenze, Italy
HTA Unit, Regione Toscana, Firenze, Italy.
出版信息
Eur J Hosp Pharm. 2022 May;29(3):e1. doi: 10.1136/ejhpharm-2020-002609. Epub 2020 Nov 30.
Abstract
摘要
相似文献
1
Chimeric antigen receptor T-cell (CART) therapy in non-Hodgkin's lymphoma: the survival gain improves as more mature follow-up data become available.嵌合抗原受体T细胞（CART）疗法治疗非霍奇金淋巴瘤：随着更成熟的随访数据可得，生存获益有所改善。
Eur J Hosp Pharm. 2022 May;29(3):e1. doi: 10.1136/ejhpharm-2020-002609. Epub 2020 Nov 30.
2
Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma.异基因造血干细胞移植和嵌合抗原受体（CAR）T 细胞治疗非霍奇金淋巴瘤。
Hematol Oncol Clin North Am. 2019 Aug;33(4):687-705. doi: 10.1016/j.hoc.2019.03.005. Epub 2019 May 10.
3
In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.体内第二代与第三代 CD19 特异性 CAR-T 细胞在 B 细胞非霍奇金淋巴瘤中的命运和活性。
Mol Ther. 2018 Dec 5;26(12):2727-2737. doi: 10.1016/j.ymthe.2018.09.009. Epub 2018 Sep 13.
4
Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.嵌合抗原受体 T 细胞疗法治疗侵袭性 B 细胞非霍奇金淋巴瘤：疗效、毒性和比较嵌合抗原受体产品。
Expert Opin Biol Ther. 2019 Nov;19(11):1157-1164. doi: 10.1080/14712598.2019.1644316. Epub 2019 Jul 25.
5
Chimeric Antigen Receptor T-Cell Therapy in the Management of Relapsed Non-Hodgkin Lymphoma.嵌合抗原受体T细胞疗法在复发非霍奇金淋巴瘤治疗中的应用
J Clin Oncol. 2021 Feb 10;39(5):476-486. doi: 10.1200/JCO.20.01749. Epub 2021 Jan 12.
6
CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin's lymphoma and tumor-supportive follicular T helper cells.CXCR5 CAR-T 细胞同时靶向 B 细胞非霍奇金淋巴瘤和肿瘤支持性滤泡辅助 T 细胞。
Nat Commun. 2021 Jan 11;12(1):240. doi: 10.1038/s41467-020-20488-3.
7
CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.嵌合抗原受体 T 细胞增强对 B 细胞成熟抗原的敏感性，用于靶向治疗 B 细胞非霍奇金淋巴瘤和多发性骨髓瘤。
Mol Ther. 2018 Aug 1;26(8):1906-1920. doi: 10.1016/j.ymthe.2018.06.012. Epub 2018 Jun 18.
8
Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma.嵌合抗原受体 T 细胞在非霍奇金淋巴瘤中的新作用。
J Natl Compr Canc Netw. 2017 Nov;15(11):1429-1437. doi: 10.6004/jnccn.2017.7045.
9
Prognostic value of FDG-PET/CT response for patient selection before chimeric antigen receptor-T-cells therapy in non-Hodgkin lymphoma.非霍奇金淋巴瘤中，氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（FDG-PET/CT）反应对嵌合抗原受体T细胞疗法前患者选择的预后价值
Hematol Oncol. 2022 Oct;40(4):796-800. doi: 10.1002/hon.2965. Epub 2022 Jan 23.
10
The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors.基因疗法在人类中的应用，即利用嵌合抗原受体重新编程T细胞特异性。
Chin J Cancer. 2014 Sep;33(9):421-33. doi: 10.5732/cjc.014.10100.
本文引用的文献
1
The Restricted Mean Survival Time as a Tool for Ranking Comparative Outcomes in a Narrative Review that Evaluates a Network of Randomized Trials: An Example Based on PCSK9 Inhibitors.限制平均生存时间作为一种工具，用于在评估随机试验网络的叙述性综述中对比较结果进行排名：基于 PCSK9 抑制剂的示例。
Am J Cardiovasc Drugs. 2021 May;21(3):349-354. doi: 10.1007/s40256-020-00444-8. Epub 2020 Oct 8.
2
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.西达基奥仑赛治疗复发或难治性大 B 细胞淋巴瘤患者的疗效和安全性（TRANSCEND NHL 001）：一项多中心无缝设计研究。
Lancet. 2020 Sep 19;396(10254):839-852. doi: 10.1016/S0140-6736(20)31366-0. Epub 2020 Sep 1.
3
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.难治性弥漫性大B细胞淋巴瘤的预后：国际SCHOLAR-1研究结果
Blood. 2017 Oct 19;130(16):1800-1808. doi: 10.1182/blood-2017-03-769620. Epub 2017 Aug 3.
Zotero 插件